Rein Therapeutics (RNTX) Cash & Equivalents (2016 - 2026)

Rein Therapeutics (RNTX) has reported Cash & Equivalents for 11 consecutive years, with $4.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 40.16% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $4.4 million (down 40.16% YoY), while the FY2025 annual figure was $3.2 million, down 75.01% from the prior year.
• Cash & Equivalents climbed to $4.4 million in Q1 2026 per RNTX's latest filing, from $3.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $21.9 million in Q2 2024 and bottomed at $3.2 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $9.7 million across 5 years, with a median of $7.6 million in 2022.
• Annual changes were most pronounced in 2023 — Cash & Equivalents jumped 233.81% — and 2025, when it slumped 77.07%.
• Rein Therapeutics' Cash & Equivalents stood at $5.2 million in 2022, then surged by 233.81% to $17.3 million in 2023, then declined by 25.8% to $12.9 million in 2024, then tumbled by 75.01% to $3.2 million in 2025, then jumped by 38.26% to $4.4 million in 2026.
• Business Quant data shows RNTX's Cash & Equivalents at $4.4 million in Q1 2026, $3.2 million in Q4 2025, and $4.0 million in Q3 2025.